AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by AstraZeneca PLC and Ionis Pharmaceuticals Inc. This approval is particularly noteworthy as Wainua is the first and only FDA-approved medication for ATTRv-PN that can be self-administered using an auto-injector. The […]